摘要
Abstract
Objective To study the clinical efficacy of rituximab combined with CHOP in treating diffuse large B cell lymphoma(DLBCL).Methods 68 cases of patients with DLBCL treated inXuchang Central Hospital from September 2012 to June 2016 were selected and randomly divided into routine group 32 cases and study group 36 cases.Routine group were provided with conventional CHO treatment,whileresearch group were provided with rituximab combined with CHOP.Patients in two groups were compared withefficacy and adverse reaction after treatment.Results Overall treatment efficacy of patients in research group was 88.89%,which was obviously higher than that ofroutine group with 59.38%,having statistical significance (P<0.05);the occurrence rate of adverse reactions such as decrease of wbc,anemia,fever and infection of research group were obviously lower than those of routine group,having statistical significance (P<0.05);there was no obvious difference in occurrence rate of adverse reactions such as constipation,transaminase elevation and nausea and vomiting between patients in two groups,with statistical significance (P>0.05).Conclusion Rituximab combined with CHOP scheme works excellently in treating diffuse large B cell lymphoma without adding adverse reactions and it is safe.关键词
淋巴瘤,大B细胞,弥漫性/抗肿瘤联合化疗方案/利妥昔单抗Key words
Lymphoma,large B-Cell,diffuse/Antineoplastic combined chemotherapy protocols/Rituximab分类
医药卫生
